Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial
Capricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company’s pivot to a narrower indication within …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







